期刊
ANNALS OF ONCOLOGY
卷 23, 期 7, 页码 1818-1825出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdr575
关键词
chemotherapy; fertility; GnRH analogues; Hodgkin lymphoma; ovarian reserve
类别
资金
- Deutsche Krebshilfe [109087]
- Bundesministerium fur Bildung und Forschung
- Kompetenznetz Maligne Lymphome
In the HD14 trial, 2x BEACOPP(escalated) + 2x ABVD (2 + 2) has improved the primary outcome. Compared with 4x ABVD, this benefit might be compromised by more infertility in women. Therefore, we analyzed gonadal function and fertility. Women < 45 years in ongoing remission at least 1 year after therapy were included. Hormone parameters, menopausal symptoms, measures to preserve fertility, menstrual cycle, pregnancies, and offspring were evaluated. Three hundred and thirty one of 579 women addressed participated (57.2%) and 263 per-protocol treated patients qualified (A = ABVD: 137, B = 2 + 2: 126, mean time after therapy 42 and 43 months, respectively). Regular menstrual cycle after treatment (A: 87%, B: 83%) and time to recovery (< 12 months) were not different. Follicle-stimulating hormone and anti-Muellerian hormone were significantly better in arm A. However, pregnancies after therapy favored arm B (A: 15%, B: 26%, P = 0.043) and motherhood rates were equivalent to the German normal population. Multivariate analysis revealed prophylactic use of gonadotropin-releasing hormone (GnRH) analogues as highly significant prognostic factor for preservation of fertility (odds ratio = 12.87, P = 0.001). Severe menopausal symptoms were frequent in women >= 30 years (A: 21%, B: 25%). Hormonal levels after 2 + 2 indicate a reduced ovarian reserve. However, 2 + 2 in combination with GnRH analogues does not compromise fertility within the evaluated observation time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据